checkAd
    Startseite > Aktien > NGM Biopharmaceuticals > Nachrichten
    NGM Biopharmaceuticals Aktie
    1,4400
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 04.04.24 Lang & Schwarz
    1,4300
     
    EUR
    5.208 STK
    Geldkurs 04.04.24
    1,4500
     
    EUR
    5.208 STK
    Briefkurs 04.04.24
    ISIN: US62921N1054 · WKN: A2N7B5 · USA

    Neueste Nachrichten

    NGM Bio Announces Closing of Tender Offer
    05.04.24 · globenewswire · NGM Biopharmaceuticals
    NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
    19.03.24 · globenewswire · NGM Biopharmaceuticals
    NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
    13.03.24 · Business Wire (engl.) · NGM Biopharmaceuticals
    NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
    11.03.24 · globenewswire · NGM Biopharmaceuticals
    NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
    27.02.24 · Business Wire (engl.) · NGM Biopharmaceuticals
    NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
    26.02.24 · Business Wire (engl.) · NGM Biopharmaceuticals
    NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
    26.02.24 · globenewswire · NGM Biopharmaceuticals
    NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
    20.02.24 · globenewswire · NGM Biopharmaceuticals
    NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
    17.01.24 · globenewswire · NGM Biopharmaceuticals
    NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
    09.01.24 · globenewswire · NGM Biopharmaceuticals
    NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting
    13.11.23 · globenewswire · NGM Biopharmaceuticals
    NGM Bio to Participate in Upcoming Investor Conferences
    07.11.23 · globenewswire · NGM Biopharmaceuticals